危重患儿替考拉宁游离与总浓度群体药代动力学
该观察性药代动力学研究在危重患儿中建立替考拉宁游离与总浓度的二室群体药代动力学模型,采用异速缩放与非线性血浆蛋白结合,并开展蒙特卡洛模拟评估达标概率。结果显示白蛋白与肾功能未显著改善模型,常用体重给药方案对多数药效靶标达标不佳。
要点
- 危重患儿替考拉宁游离分数变异大,白蛋白水平不能预测该变异。
- 常用体重给药方案对多数药效靶标达标不佳。
- 可考虑开展游离浓度治疗药物监测以优化给药。
核心结论
- 成功表征危重患儿替考拉宁游离与总浓度药代动力学。
- 白蛋白水平不能预测游离分数的高变异性。
- 常用给药方案对多数药效靶标达标不佳。
研究设计与样本
- 观察性药代动力学研究,采集首剂后及假定稳态血样。
- 采用标准序贯法开展群体药代动力学分析。
- 用蒙特卡洛模拟基于已发表药效靶标进行达标概率分析。
主要发现
- 二室模型加异速缩放与非线性血浆蛋白结合最佳描述数据。
- 纳入白蛋白或肾功能均未显著改善模型。
- 最终模型未支持纳入其他协变量。
关键数值与推荐
- 达标概率分析显示标准给药方案对多数拟定靶标达标不理想。
- 无论评估何种药代动力学/药效学靶标,最常用给药方案达标均差。
临床怎么用
- 危重患儿使用替考拉宁时不应仅依据白蛋白水平推断游离药物暴露。
- 可考虑对游离浓度开展治疗药物监测以指导个体化给药。
- 常用体重给药方案可能需重新评估以达到药效靶标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Teicoplanin is a highly protein-bound antibiotic, increasingly used to treat serious Gram-positive infections in critically ill children. Maturational and pathophysiological intensive care unit-related changes often lead to altered pharmacokinetics. In this study, the objectives were to develop a pediatric population-pharmacokinetic model of unbound and total teicoplanin concentrations, to investigate the impact of plasma albumin levels and renal function on teicoplanin pharmacokinetics, and to evaluate the efficacy of the current weight-based dosing regimen. METHODS: An observational pharmacokinetic study was performed and blood samples were collected for quantification of unbound and total concentrations of teicoplanin after the first dose and in assumed steady-state conditions. A population-pharmacokinetic analysis was conducted using a standard sequential approach and Monte Carlo simulations were performed for a probability of target attainment analysis using previously published pharmacokinetic-pharmacodynamic targets. RESULTS: A two-compartment model with allometric scaling of pharmacokinetic parameters and non-linear plasma protein binding best described the data. Neither the inclusion of albumin nor the renal function significantly improved the model and no other covariates were supported for inclusion in the final model. The probability of target attainment analysis showed that the standard dosing regimen does not satisfactory attain the majority of the proposed targets. CONCLUSIONS: We successfully characterized the pharmacokinetics of unbound and total teicoplanin in critically ill pediatric patients. The highly variable unbound fraction of teicoplanin could not be predicted using albumin levels, which may support the use of therapeutic drug monitoring of unbound concentrations. Poor target attainment was shown for the most commonly used dosing regimen, regardless of the pharmacokinetic-pharmacodynamic target evaluated.
引用
- Aulin LBS, De Paepe P, Dhont E, et al. Population Pharmacokinetics of Unbound and Total Teicoplanin in Critically Ill Pediatric Patients. Clin Pharmacokinet. 2020. PMID: 33030704. doi:10.1007/s40262-020-00945-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。